|
(Health-NewsWire.Net, August 21, 2015 ) Glaucoma is a leading cause of preventable blindness globally. This chronic progressive optic neuropathy causes irreversible vision loss through damage to the optic nerve. There are currently no treatments that can directly prevent this damage, and all commercially available glaucoma therapies focus on lowering elevated intraocular pressure (IOP), a known risk factor for glaucoma development and progression. The launch of fixed-dose combination (FDC) products, which combine drugs from these various classes, will continue to be a source of significant growth in this market. The glaucoma market is about to enter a phase of new growth with the arrival of first-in-class drugs, such as Aeries Rhopressa, Bausch & Lombs Vesneo (latanoprost bunod), and Inoteks trabodenoson into the 7MM during the forecast period, which will generate additional growth in the global glaucoma market.
To Browse a Full Report with TOC: http://www.researchmoz.us/pharmapoint-glaucoma-global-drug-forecast-and-market-analysis-to-2023-report.html
Key Findings
The main driver of growth in the glaucoma market will be the introduction of first-in-class drugs over the forecast period. The launch of three first-in-class therapies will grow this market. New fixed-dose drugs entering the 7MM will also act as a stimulant for growth.
The biggest barrier for growth in the glaucoma market will be the increasing use of generic latanoprost across the 7MM. The low cost of this therapy will increase the pressure on new drugs hoping to enter these markets to show drug cost-effectivness. This is likely to have a negative impact on these markets, as regulatory bodies are adopting stricter criterial for new drug approvals and reimbursement listing.
The largest unmet needs mainly reflect the notorious problem of poor patient adherence to therapy. Simplifying dosing regimens is an important consideration for companies developing drugs to treat these patients.
Scope
Overview of glaucoma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
Annualized Glaucoma market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the glaucoma therapeutics market.
Pipeline analysis: focus on the eight late-stage pipeline glaucoma drugs discussing emerging trends as well as overview of earlier phase drugs.
Analysis of the current and future market competition in the global glaucoma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
To Download Sample Report with TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=318824
Reasons to buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
Develop business strategies by understanding the trends shaping and driving the global glaucoma therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global glaucoma therapeutics market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the global glaucoma therapeutics market from 2013-2023.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
To Read the Complete Report with Toc Visit: http://www.researchmoz.us/pharmapoint-glaucoma-global-drug-forecast-and-market-analysis-to-2023-report.html
Download Sample copy of this report at: http://www.researchmoz.us/enquiry.php?type=sample&repid=318824
About ResearchMoz
ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
Albany NY - 12207
United States
Email: sales@researchmoz.us
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-621-2074
Researchmoz Global Pvt.Ltd
Researchmoz
+1-518-621-2074
sales@researchmoz.us
Source: EmailWire.Com 
|
